DMXE
deoxymethoxetamine
Viewing r1 — May 7, 2026
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
DMXE (deoxymethoxetamine) is a synthetic dissociative of the arylcyclohexylamine class — the same family as ketamine and PCP. It is structurally nearly identical to MXE, differing by a single chemical group. It blocks glutamate signaling in the brain, producing the disconnection from body, environment, and self characteristic of dissociatives.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
ketamine, methoxetamine, phencyclidine +3 moreketamine, methoxetamine, phencyclidine, deschloroketamine, 2-FDCK, O-PCE show less
DMXE emerged on online research chemical markets in October 2020, after MXE was progressively banned across major jurisdictions.[2] That single chemical change was enough to sidestep MXE's scheduling language while preserving its dissociative effects. It circulates through online vendors, remains unscheduled at the U.S. federal level, and has been detected in drug samples in Europe, Japan, and New England.
Subjective effects include euphoria, dissociation, cognitive disconnection, geometric visual patterns, and unusual sociability. The experience is warm and introspective — lighter than MXE, gently stimulating at lower doses and deeply immersive at higher ones. Confusion, amnesia, a strong compulsive redosing urge during the comedown, and nausea are common unwanted effects.
No physical dependence is documented, but compulsive within-session redosing is widely reported. Hazards documented in related compounds include seizures and cardiovascular stress,[3] persistent psychosis,[4] and bladder damage with chronic use;[5] combining with serotonin-active drugs risks fatal overheating. Only three peer-reviewed papers address DMXE directly[1][6][7] — no human safety data exist, and the safe dose ceiling is unknown.
History[edit]
History
Discovery
DMXE has no documented history before 2020. It appeared on online research chemical markets around October 2020, positioned as a replacement for MXE after MXE was progressively scheduled across multiple jurisdictions.[2] The chemical change was minimal — a methyl group replaced MXE's methoxy group — producing a compound not named in existing drug law while preserving dissociative activity.
Forensic detection
Forensic laboratories in Slovenia first identified DMXE in December 2020,[8][9] followed by Denmark in February 2021. Japan followed with the first peer-reviewed forensic identification in 2022.[6] In the United States, only two samples had been catalogued by the CFSRE as of October 2025.[9]
Scientific characterization
The first pharmacological data were published in 2022, confirming DMXE blocks the same glutamate receptor channel site as ketamine and PCP.[1] A 2025 study achieved the first separation of DMXE's two mirror-image molecular forms.[7] No further pharmacological, toxicological, or clinical studies have been published as of May 2026.
Chemistry[edit]
Chemistry
Structural class
DMXE belongs to the arylcyclohexylamine family — the same chemical class as ketamine, PCP, and MXE. It is a direct structural analog of MXE, differing by a single substitution on the phenyl ring: a methyl group replaces MXE's methoxy group.[2] Its molecular formula is C₁₅H₂₁NO (molecular weight 231.33 g/mol).
Stereochemistry
DMXE has one chirality center, producing two mirror-image forms (enantiomers). It is sold as a racemic mixture — an equal mixture of both. Seibert et al. achieved the first separation of these enantiomers in 2025.[7] Their relative potency is unknown, which may partly explain batch-to-batch variation in effects.
Pharmacology[edit]
Pharmacology
Mechanism of action
DMXE blocks the brain's main excitatory signaling channel — the NMDA glutamate receptor — by lodging inside the open channel at the same site used by ketamine and PCP.[1] This blockade interrupts normal brain communication, producing the characteristic dissociative state. In the only published potency measurement, DMXE's glutamate-blocking strength was comparable to MXE in mouse neural tissue.[1]
By structural analogy with MXE — which also affects SERT activity[10] — DMXE may interact with serotonin signaling as well. This has not been confirmed. The methyl-for-methoxy substitution could alter these secondary effects in either direction.
Pharmacokinetics
No human pharmacokinetic data have been published for DMXE. Based on MXE's metabolism, the liver likely breaks DMXE down primarily by removing the ethyl group from its nitrogen, producing a metabolite called nor-DMXE.[11] How quickly this happens and whether nor-DMXE is active is unknown.safety citation needed
Neuroscience[edit]
Neuroscience
Where it acts
DMXE disrupts communication between the cortex and the thalamus — the brain's sensory relay station.[12] When that relay is interrupted, sensory input stops assembling into a coherent experience of body and surroundings. The result is the characteristic dissociative state: progressive detachment from body, environment, and self.
Blocking glutamate receptors on inhibitory neurons paradoxically increases activity in other cells. This excitatory rebound effect may explain the stimulating quality users report at lower doses.
Why it matters
NMDA-blocking compounds — including ketamine — can promote structural rewiring of brain connections.[12] Related MXE analogs have shown antidepressant-like effects in animal studies.[13] Whether DMXE triggers the same changes at typical doses is unknown, but if it does, use may produce lasting circuit-level changes beyond the period of intoxication.
Does DMXE promote structural brain rewiring comparable to ketamine? The methyl substitution's effects on plasticity signaling are uncharacterized. Given that ketamine's mirror-image forms differ four-fold in potency, DMXE's enantiomeric profile could matter significantly.[7]
Subjective Effects[edit]
Subjective Effects
DMXE produces an unusually warm dissociative state. At lower doses it feels sociable and gently stimulating — more open than ketamine's clinical detachment. As the dose rises, that warmth gives way to deeper cognitive drift, geometric visual patterns, and inward immersion.
Within its class, DMXE is most often compared to MXE, which it was designed to replace. The experience is typically described as milder at equivalent dissociative depth — less psychologically intense, with greater warmth and a longer duration than ketamine.
Effect Grid
Clear dissociative effects emerge. Motor control impairment becomes noticeable — walking is unsteady and fine motor tasks become difficult. Bodily dissociation deepens: numbness spreads, and the boundary between body and environment begins to blur. Euphoria intensifies with a warm, rounded quality frequently compared to MXE.
Introspection enhancement is a defining feature at this tier. Thought patterns turn inward, and contemplative states arise naturally. Mild geometric visual distortions appear with eyes closed — patterning in cool-toned palettes. Music enhancement is prominent, and time alteration becomes apparent. Auditory distortion may add a reverberant quality to sounds.
This is the tier where compulsive redosing urge is most consequential — the desire to extend or deepen the experience during the offset phase is commonly reported. Pre-portioning doses and removing access to remaining material is strongly recommended.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Touch suppression · Vestibular distortion · Ganzfeld effect · Sensory deprivation · Sleep-transition hallucinations · Auditory distortion · Music enhancement · Visual acuity suppression · Visual haze / noise · Touch enhancement · Brightness alteration · Color alteration · Auditory suppression · Holotropic state · Peripheral vision distortion · Tracers · Visual drifting · Visual morphing · Color suppression · Dreaming suppression · Color enhancement · Tinnitus · After-images · Auditory misinterpretation · Dreaming enhancement · Geometry · Sound sensitivity · Visual diffraction · Taste suppression · Visual magnification · Environmental patterning · Peripheral misidentification · Synesthesia · Visual breathing · Visual melting · Internal hallucinations · Visual processing suppression · External hallucinations · Object transformations · Perspective hallucinations · Environmental orbism / cubism · Visual flipping · Auditory hallucinations · Object activation · Visual recursion · Shadow people
Sleep-transition hallucinations · Auditory distortion · Music enhancement · Visual acuity suppression · Visual haze / noise · Touch enhancement · Brightness alteration · Color alteration · Auditory suppression · Holotropic state · Peripheral vision distortion · Tracers · Visual drifting · Visual morphing · Color suppression · Dreaming suppression · Color enhancement · Tinnitus · After-images · Auditory misinterpretation · Dreaming enhancement · Geometry · Sound sensitivity · Visual diffraction · Taste suppression · Visual magnification · Environmental patterning · Peripheral misidentification · Synesthesia · Visual breathing · Visual melting · Internal hallucinations · Visual processing suppression · External hallucinations · Object transformations · Perspective hallucinations · Environmental orbism / cubism · Visual flipping · Auditory hallucinations · Object activation · Visual recursion · Shadow people
Body schema distortion · Dizziness · Nystagmus (eye wobbles) · Body high · Muscle relaxation · Spontaneous body sensations · Tingling / electric sensations · Vibrations / buzzing · Appetite suppression · Bodily heaviness · Headache · Heart rate perception changes · Laughter fits · Nausea · Physical fatigue · Pupil dilation · Stimulation · Vasoconstriction · Wakefulness · Bodily lightness · Dry mouth · Insomnia · Nasal congestion · Tactile euphoria · Increased urination · Trembling · Vomiting · Bodily pressures · Brain zaps · Breathing alteration · Excessive sweating · Involuntary body movements · Muscle tension · Restlessness · Bodily dissociation · Tactile hallucination · Phantom limb sensations
Body high · Muscle relaxation · Spontaneous body sensations · Tingling / electric sensations · Vibrations / buzzing · Appetite suppression · Bodily heaviness · Headache · Heart rate perception changes · Laughter fits · Nausea · Physical fatigue · Pupil dilation · Stimulation · Wakefulness · Bodily lightness · Dry mouth · Insomnia · Nasal congestion · Tactile euphoria · Increased urination · Trembling · Vomiting · Bodily pressures · Brain zaps · Breathing alteration · Excessive sweating · Involuntary body movements · Muscle tension · Restlessness · Bodily dissociation · Tactile hallucination · Phantom limb sensations
Information processing suppression · Memory fragmentation · Memory suppression · Thought disorganization · Analysis suppression · Cognitive euphoria · Cognitive fatigue · Immersion enhancement · Introspection enhancement · Aesthetic enhancement · Language suppression · Motivation suppression · Novelty enhancement · Suggestibility enhancement · Thought deceleration · Creativity enhancement · Humor enhancement · Cognitive flexibility · Conceptual thinking · Delusions of sobriety · Multiple thought streams · Openness enhancement · Pattern recognition suppression · Thought connectivity · Thought loops · Focus enhancement · Motivation enhancement · Aesthetic suppression · Creativity suppression · Memory replays · Cognitive dysphoria · Pattern recognition enhancement · Information processing enhancement · Analysis enhancement · Amnesia · Delirium · Delusions
Thought disorganization · Analysis suppression · Cognitive euphoria · Cognitive fatigue · Immersion enhancement · Introspection enhancement · Aesthetic enhancement · Language suppression · Motivation suppression · Novelty enhancement · Thought deceleration · Creativity enhancement · Humor enhancement · Cognitive flexibility · Conceptual thinking · Delusions of sobriety · Multiple thought streams · Openness enhancement · Pattern recognition suppression · Thought connectivity · Thought loops · Focus enhancement · Motivation enhancement · Aesthetic suppression · Creativity suppression · Memory replays · Cognitive dysphoria · Pattern recognition enhancement · Information processing enhancement · Analysis enhancement · Amnesia · Delirium · Delusions
Emotional suppression · Simultaneous emotions · Anxiety · Catharsis · Emotional lability · Empathy enhancement · Empathy suppression · Anhedonia · Dysphoria · Irritability
Emotional lability · Empathy enhancement · Empathy suppression · Anhedonia · Dysphoria · Irritability
Social connection · Disinhibition · Sociability suppression · Compulsive behavior reduction · Trust enhancement · Automaticity · Craving · Emotional susceptibility · Sociability enhancement · Communication enhancement · Flow state · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Trust enhancement · Automaticity · Craving · Emotional susceptibility · Sociability enhancement · Communication enhancement · Flow state · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Time cessation
Transpersonal feelings · Voidness · Death-rebirth sequence · Entity contact · Near-death experience · Transpersonal visions
Near-death experience · Transpersonal visions
Mindfulness enhancement · Recursive awareness
Timeline
Slower emergence than insufflated route — a gentle shift in awareness and mild bodily warmth over 15–30 minutes.
Extended build with a more sedating quality than the insufflated route. Dissociation and euphoria develop gradually.
Longer, more rounded peak than insufflated. Deeper sedation component; introspective and dissociative effects are sustained but less sharp in onset.
Prolonged resolution with lingering sedation. Environmental awareness returns gradually. Redosing urge may emerge but is less acute than with insufflation.
Residual cognitive softness and mood lift, similar to insufflated route but potentially more prolonged due to slower elimination.
⚠ Do not drive or operate heavy machinery for at least 8 hours after last dose.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- Negligible
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- ketamine · methoxetamine · phencyclidine
Safety
DMXE has no published toxicological profile. No lethal dose, no therapeutic index, and no controlled human safety data exist. All safety information below is derived from class-level evidence (ketamine, MXE, PCP analogs), structural inference, and community reports. The margin between a strong and dangerous dose is unknown.Toxicity
Acute toxicity
No cases of acute DMXE toxicity appear in peer-reviewed literature.[9] No lethal dose data have been published in any species. safety citation needed
Class-level acute risks for arylcyclohexylamines include:
- Seizures and abnormal heart rhythms: Documented in acute MXE intoxication[3]
- Rapid heart rate and elevated blood pressure: Reported across the class[3]
- Muscle breakdown and kidney injury: Documented in a structural relative sharing DMXE's 3-methylphenyl ring[15] inferred
- Fatal outcome: A death involving O-PCE — a compound sharing DMXE's core structure — occurred in combination with venlafaxine[16]
Chronic toxicity
Chronic heavy ketamine use causes progressive bladder damage — inflammation, scarring, and in severe cases kidney failure.[5][17] Whether DMXE carries the same risk is unknown; this is a class-level concern for all arylcyclohexylamine dissociatives used repeatedly. inferred
Repeated NMDA-blocking drug use is associated with brain cell damage in animal models.[14] A single intravenous MXE dose produced psychotic symptoms and measurable metabolic changes in the brain.[4] Similar persistent effects have been documented with other arylcyclohexylamines.[18]
Psychological Risks
High doses can produce paranoia, delusions, thought disorganization, and loss of reality testing. Community reports describe confusion and delirium at heavy doses (60+ mg insufflated).[19][20]
Psychosis documented in related compounds[4][18] has persisted beyond the acute intoxication period. Memory loss and blackout at heavy doses,[19] combined with impaired motor control, increase the risk of accidental injury. People with a personal or family history of psychosis are at elevated risk.
Tolerance & Dependence
No controlled studies on DMXE tolerance or dependence exist. Tolerance builds rapidly with repeated use,[19][20] and cross-tolerance with ketamine, MXE, and other NMDA antagonists is expected but unconfirmed for DMXE specifically.
Physical dependence has not been characterized. The more prominent concern is psychological: a compulsive compulsive redosing urge during the comedown is widely reported,[19] and at least one report documents addiction and habituation.[20] No formal dependence assessments have been conducted. safety citation needed
Drug Interactions
No published drug interaction studies exist for DMXE — all interaction data represent class-level inference. inferred If DMXE shares MXE's SERT activity,[10] combining it with SSRIs, SNRIs, or monoamine oxidase inhibitors risks serotonin syndrome — dangerous overheating and seizures that can be fatal.[19] A death involving the related compound O-PCE combined with the antidepressant venlafaxine illustrates this risk.[16]
Depressants (opioids, alcohol, benzodiazepines) add sedation and suppress breathing; the dissociative state impairs cough and gag reflexes, increasing choking risk. Stimulants compound cardiovascular strain from DMXE's effects on heart rate and blood pressure. Other NMDA antagonists risk dangerously deep sedation.
Contraindications
No substance-specific contraindication data exist. The following are derived from class-level evidence and pharmacological mechanism. inferred
Absolute contraindications:
- Psychotic disorders (personal or family history): NMDA antagonists can trigger persistent psychosis[4][18]
- Concurrent MAO inhibitor use: Dangerously intensified serotonergic and stimulant effects safety citation needed
- Concurrent high-dose SNRI/SSRI use: Serotonin syndrome risk; the O-PCE + venlafaxine fatality is the most relevant case[16]
Relative contraindications:
- Heart conditions: Rapid heart rate and elevated blood pressure are class-level effects[3]
- Kidney impairment: Reduced clearance and muscle breakdown risk by structural parallel[15]
- Liver impairment: Impaired breakdown may alter drug levels unpredictably[11]
- Seizure history: Seizures documented in MXE intoxication[3]
- Pregnancy: NMDA receptor blockade may disrupt brain development; no reproductive safety data safety citation needed
- Bladder or urinary tract disease: Class-level risk of progressive damage with repeated use[5]
Harm Reduction[edit]
Harm Reduction
Forms & Identification
DMXE arrives as an unregulated white to off-white powder with no quality controls. Multiple dissociative powders look identical, so reagent testing is necessary — not to confirm DMXE specifically, but to rule out dangerous substitutions such as synthetic opioids or stimulants.
Use fentanyl test strips on every batch. Potency varies substantially between vendors and between batches, making dose consistency unreliable even with a milligram scale.
Guidelines
- Test every batch with reagent kits and fentanyl test strips before use
- Weigh doses on a milligram-scale balance — do not estimate powder by eye
- Start with a low dose and wait at least 90 minutes before considering redosing, especially oral
- Have a sober companion present, particularly at moderate or higher doses
- Keep water accessible but avoid consuming large quantities — stay hydrated without overdrinking
- Clear the environment of sharp objects, open flames, and fall hazards before onset
- Do not drive or operate machinery for at least 8 hours after use
- Predetermine the total dose for the session and set the remaining material aside — the compulsive redosing urge is widely reported and can escalate dose beyond intended levels
Set & Setting
Dissociative experiences are strongly shaped by mindset and environment. Use in a calm, familiar setting with a sober companion present — especially at higher doses, where motor control and judgment are significantly impaired. Avoid physically hazardous environments: heights, water, traffic.
Prior dissociative experience significantly shapes how DMXE feels. First-time users should start well below their intended dose and allow the full experience to run before evaluating.
Aftercare & integration. The hours following a dissociative experience may include residual mental fog, emotional flatness, or a sense of unreality. These aftereffects typically resolve within 24–48 hours. Rest, light food, and quiet activity support recovery.
If the experience was psychologically intense, allow time before returning to demanding tasks. Journaling or conversation with a trusted person can help integrate unusual perceptual or cognitive experiences. Persistent unreality, depersonalization, or cognitive difficulty beyond 72 hours warrants professional consultation.
Recovery & Support
DMXE's compulsive redosing pattern can develop into habitual use, particularly when used to manage emotional distress. If use has become frequent or difficult to control, support is available.
SAMHSA National Helpline: 1-800-662-4357 (US, free, confidential, 24/7). Harm reduction communities provide peer support for dissociative use concerns. Professional substance use counseling — particularly for dissociative and ketamine use patterns — can help establish healthier patterns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable dissociation is not inherently dangerous, but the following signs require immediate help: seizure activity, loss of consciousness with inability to rouse, vomiting while unconscious or deeply dissociated, chest pain, blue or grey lips, or signs of extreme agitation with self-harm risk.
Immediate steps:
- 1. Call emergency services immediately if the person is unresponsive, seizing, or has stopped breathing
- 2. Place an unresponsive breathing person in the recovery position (on their side) to prevent choking on vomit
- 3. Do not attempt to restrain someone who is agitated unless they are in immediate danger of harming themselves
- 4. Do not induce vomiting
- 5. Stay with the person and monitor breathing until help arrives
What to tell the dispatcher: Name the substance (DMXE, a dissociative), the approximate amount taken, the time of ingestion, the route, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for NMDA antagonist intoxication. Treatment is supportive.
Legal Status[edit]
Legal Status
DMXE occupies a legal gray zone in most jurisdictions — specifically controlled in some countries under broad arylcyclohexylamine or novel psychoactive substance laws, and unscheduled in others.[8][9]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not federally scheduled | DMXE is not listed in DEA schedules. MXE (parent compound) placed in Schedule I effective July 6, 2022.[21] Federal Analogue Act (21 U.S.C. § 813) may apply given structural and pharmacological similarity to Schedule I MXE. |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled under broad arylcyclohexylamine provisions. Penalties: up to 5 years imprisonment for possession, 14 years for supply.citation needed |
| Germany | Controlled (NpSG) | Restricted under the Neue-psychoaktive-Stoffe-Gesetz. Limited to industrial and scientific use.citation needed |
| Japan | Designated substance (likely) | DMXE identified in seized illegal products;[6] specific designation status under pharmaceutical law not confirmed via official government source. |
| European Union | EMCDDA EWS monitored | Tracked via Early Warning System since 2020–2021. Individual member states may impose additional controls.[8] |
| Canada | Possibly Schedule I (CDSA) | Secondary source claim; editorial verification against Controlled Drugs and Substances Act schedules required.citation needed |
| Australia | Controlled (requires license) | Secondary source claim; verification against SUSMP/TGA schedules required.citation needed |
Analog Act considerations
In the United States, the Federal Analogue Act may treat DMXE as a Schedule I substance because it differs from Schedule I MXE by a single functional group and shows comparable NMDA-blocking potency.[1][21] The Act has been applied to other arylcyclohexylamine analogs.[22]
references
- [1]
- [2] ^abcWallach J, Brandt SD (2018) 1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_148
- [3]
- [4] ^abcdMoccia L, Tofani A, Mazza M, Covino M, Martinotti G, Schifano F, Janiri L, Di Nicola M (2019) Dorsolateral Prefrontal Cortex Impairment in Methoxetamine-Induced Psychosis: An 18F-FDG PET/CT Case Study — Journal of Psychoactive Drugs doi:10.1080/02791072.2019.1578444
- [5] ^abcCastellani D, Pirola GM, Gubbiotti M, Rubilotta E, Gudaru K, Gregori A, Dellabella M (2020) What urologists need to know about ketamine-induced uropathy: A systematic review — Neurourology and Urodynamics doi:10.1002/nau.24341
- [6] ^abcTanaka R, Kawamura M, Mizutani S, Hakamatsuka T, Kikura-Hanajiri R (2022) Identification of Three Arylcyclohexylamines (MXPr, MXiPr, and DMXE) in Illegal Products — Yakugaku Zasshi (Journal of the Pharmaceutical Society of Japan) doi:10.1248/yakushi.21-00235